Andrea Navarro-Gras
Bergen, 5009, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy.
Journal: Cancers
Published: August 17, 2021
Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival.
Journal: Cancers
Published: May 23, 2019
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
Journal: British journal of cancer
Published: April 26, 2019
Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions.
Journal: Frontiers in immunology
Published: March 02, 2018
Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients.
Journal: Oncoimmunology
Published: January 20, 2017
Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients.
Journal: Cancer research
Published: April 25, 2016
Therapeutic potential and challenges of natural killer cells in treatment of solid tumors.
Journal: Frontiers in immunology
Published: February 20, 2015
NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: November 09, 2014
Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma.
Journal: PloS one
Published: March 19, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026